Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical Inc. (LFCR) provides essential contract development and manufacturing services for sterile injectable pharmaceuticals and hyaluronic acid production. This news hub offers investors and industry professionals centralized access to official updates and analysis.
Track critical developments including regulatory milestones, manufacturing partnerships, and product innovation announcements. Our curated collection ensures timely access to earnings reports, facility expansions, and quality certifications that demonstrate LFCR's CDMO leadership.
All content undergoes rigorous verification to maintain accuracy and compliance with financial disclosure standards. Users benefit from organized updates on aseptic processing advancements, fermentation technology, and strategic collaborations within the biopharmaceutical sector.
Bookmark this page for streamlined monitoring of Lifecore Biomedical's operational progress and market positioning. Combine these verified updates with broader industry research to inform your analysis of this specialized pharmaceutical manufacturer.
Lifecore Biomedical (NASDAQ: LFCR) announced on April 14, 2023, that it received a notice from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the period ended February 26, 2023. While the notice does not immediately affect the listing or trading of LFCR's securities, the Company has 60 days to submit a compliance plan, with a possible extension of 180 days to file the Form 10-Q if the plan is accepted. Lifecore is actively working to complete the filing to restore compliance and has emphasized its commitment to addressing the situation promptly.
FAQ
What is the current stock price of Lifecore Biomedical (LFCR)?
What is the market cap of Lifecore Biomedical (LFCR)?
